Chemomab Therapeutics Ltd is a clinical-stage biotechnology company focused on developing therapeutics for fibro-inflammatory diseases. The company combines bioscience with medical research to create drug therapies targeting fibrosis and cancer. Its primary customers include healthcare providers and patients in need of treatments for these conditions. Chemomab operates in the biotechnology sector, primarily in the United States and other global markets.
